PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine (Lantus®)
Drug: Inhaled Human Insulin (Exubera®)

First Posted Date: 2006-10-23

Last Posted Date: 2015-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 261

Registration Number: NCT00391027

Locations: 🇨🇭
Pfizer Investigational Site, St. Gallen, Switzerland

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Phase 3

Terminated

Conditions: Hypertension

Interventions: Drug: placebo
Drug: ramipril

First Posted Date: 2006-10-19

Last Posted Date: 2012-06-11

Lead Sponsor: Pfizer

Target Recruit Count: 422

Registration Number: NCT00389519

Locations: 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇦🇷
Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina
🇦🇷
Hospital General Interzonal "Dr. José Penna", Buenos Aires, Argentina

and more 97 locations

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Neoplasms

Interventions: Drug: AG-013736

First Posted Date: 2006-10-18

Last Posted Date: 2013-11-25

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT00389441

Locations: 🇬🇧
Pfizer Investigational Site, Glasgow, United Kingdom

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: rLP2086

First Posted Date: 2006-10-13

Last Posted Date: 2014-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 127

Registration Number: NCT00387725

Locations: 🇦🇺
Royal Children's Hospital, Herston, Queensland, Australia
🇦🇺
Department of Paediatrics and Child Health, Woden, Australia
🇦🇺
National Centre for Immunisation, Westmead, Australia

and more 6 locations

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Duloxetine 60 mg/day
Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Drug: Placebo

First Posted Date: 2006-10-04

Last Posted Date: 2012-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 638

Registration Number: NCT00384033

Locations: 🇺🇸
Pfizer Investigational Site, Brown Deer, Wisconsin, United States

Methods Study to Characterize Early Indicators of Weight Loss in People

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: caloric restriction - 10%
Behavioral: caloric restriction - 25%
Behavioral: caloric restriction - 50%
Behavioral: caloric restriction - Control

First Posted Date: 2006-10-03

Last Posted Date: 2009-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 57

Registration Number: NCT00383253

Locations: 🇦🇺
Pfizer Investigational Site, North Adelaide, South Australia, Australia

An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: placebo
Drug: PH-797804

First Posted Date: 2006-10-02

Last Posted Date: 2021-08-20

Lead Sponsor: Pfizer

Target Recruit Count: 305

Registration Number: NCT00383188

Locations: 🇧🇷
Hospital Heliópolis - PAM, São Paulo, SP, Brazil
🇨🇿
NZZ Bormed, s.r.o., Ostrava - Trebovice, Czechia
🇮🇳
Department of Rheumatology, CARE Hospital, Hyderabad, Andhra Pradesh, India

and more 45 locations

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

Phase 4

Completed

Conditions: Coronary Arteriosclerosis

First Posted Date: 2006-09-27

Last Posted Date: 2006-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT00380939

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)

First Posted Date: 2006-09-14

Last Posted Date: 2018-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00376168

Locations: 🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇮🇱
Rambam Medical Center, Haifa, Israel

and more 8 locations

Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

Phase 1

Withdrawn

Conditions: Obesity

First Posted Date: 2006-09-14

Last Posted Date: 2015-04-22

Lead Sponsor: Pfizer

Registration Number: NCT00376285

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy